

Amneal Pharmaceuticals Agrees to Acquire Kashiv BioSciences

Creating a Global Biosimilar Leader

April 22, 2026

Amneal

Cautionary statement on forward looking statements and non-GAAP financial measures

The foregoing contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “hope,” “hopeful,” “likely,” “may,” “optimistic,” “possible,” “potential,” “preliminary,” “project,” “should,” “will,” “would” or the negative or plural of these words or similar expressions or variations. Forward-looking statements are made based upon management’s current expectations and beliefs and are not guarantees of future performance, and include statements regarding the transaction agreement and the transaction, including the expected time period to consummate the transaction, the anticipated benefits (including synergies) of the transaction and integration and transition plans, the transaction’s closing date, opportunities and anticipated future performance (including pro forma combined performance), expectations regarding our net leverage, our ability to become America’s top affordable medicines company, statements regarding the global biosimilars and affordable medicines markets and the company’s position and opportunities therein and our ability to expand internationally, and statements regarding our business and results of operations. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. These factors include, among others (i) the completion of the proposed transaction on the anticipated terms and timing; (ii) the satisfaction of other conditions to the completion of the proposed transaction, including obtaining required shareholder and regulatory approvals; (iii) the risk that the Company’s stock price may fluctuate during the pendency of the proposed transaction and may decline if the proposed transaction is not completed; (iv) potential litigation relating to the proposed transaction that could be instituted against the Company or its directors, managers or officers, including the effects of any outcomes related thereto; (v) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, including during the pendency of the proposed transaction; (vi) the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction and integration matters; (vii) legislative, regulatory and economic developments; (viii) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, outbreaks of war or hostilities or global pandemics, as well as management’s response to any of the aforementioned factors; (ix) the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (x) unexpected costs, liabilities or delays associated with the transaction; (xi) the response of competitors to the transaction; (xii) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction; and (xiii) other risks set forth under the heading “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

This presentation includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted gross margin, adjusted net income, adjusted diluted EPS, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management. These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included in the appendix, and should not rely on any single financial measure to evaluate the Company’s business. A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth herein.

The Company’s 2026-2030 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Today's presenters

Highly Strategic Deal Creates Global Biosimilar Leader

Massive opportunity given upcoming biologic LOEs

Chirag Patel
Co-founder



Biosimilar Portfolio & Pipeline

Platform to launch multiple biosimilars each year

Chintu Patel
Co-founder



Significant Growth Potential & Value Creation


Extends Amneal's growth profile into 2030s

Tasos Konidaris
EVP & CFO



Q&A

Acquisition creates a global biosimilar leader



HIGHLY STRATEGIC & COMPLEMENTARY TRANSACTION

Direct access to **\$300B+ global biologic LOEs over next decade** – with \$234B in U.S.

Well positioned as integrated biosimilar leader with **seamless integration** of Kashiv's R&D & manufacturing with Amneal's commercial scale

Low execution risk as it builds on ten-year plus relationship



COMBINED BIOSIMILAR PORTFOLIO AND CAPABILITIES

Multiple biosimilar launches each year – growing over time

20+ biosimilar pipeline projects – mix of large biologics and smaller < \$5B molecules

Robust R&D capabilities enables parallel development and commercialization



DIVERSIFIES AND EXTENDS AMNEAL'S GROWTH PROFILE

Adds biosimilars as a key **growth pillar** within Affordable Medicines

Accelerates **international expansion and growth**

Extends Amneal's durable growth profile into 2030s



ATTRACTIVE DEAL STRUCTURE AND SIGNIFICANT SYNERGIES

Prudent mix of upfront consideration (cash & equity) and **potential success-based milestones** over time

Minimal impact to leverage profile with **clear path to be below 3x net leverage by 2028**

Substantial financial synergies

Kashiv BioSciences is an established global biosimilar platform

12+
years of experience

4
biologics R&D & manufacturing facilities

600+
employees globally


\$900M+
capital invested since founding in 2013

Chicago, IL: U.S. FDA- approved facility with two commercial biosimilars (RELEUKO® and FYLNETRA®) and fill-and-finish capabilities

Piscataway, NJ: Monoclonal antibodies and fusion proteins production; ~6,000L capacity installed with ~24,000L total planned; R&D facility with microbiology labs

Pipari, India: Next generation facility with total planned capacity of ~50,000L

Ahmedabad, India: R&D and GMP pilot facility focused on range of biologics



WHAT KASHIV ENHANCES



FDA, MHRA, ANVISA, and Health Canada-approved U.S. sites accelerate regulatory timelines



Differentiated pipeline across wide range of modalities and new complex indications



Scaled R&D and manufacturing enables parallel commercialization and development reducing time to market



Dual U.S. and India sites provide supply chain reliability and substantial cost advantages

Adds leading biologic R&D and manufacturing expertise

R&D

- **End-to-end biologics capabilities** spanning robust analytical development and protein characterization, clinical study design and regulatory expertise
- **Expertise across major biological technology platforms** including microbials, mAbs, fusion proteins, bispecifics, and cytokines—**covering the majority of biologics**
- **~300 scientists with a decade of experience** in biosimilar platform build and execution
- **Proven track record of multiple approvals** and capacity to develop 3–5 biosimilars per year

Manufacturing

- **Dual-pronged manufacturing network across the U.S. & India** balancing speed-to-market with competitive cost position
- **Scaled drug substance capacity to ~75,000L expected by 2028** (from ~26,000L in 2026)
- **State-of-the-art, modular manufacturing** enabling flexible pipeline development with latest single-use technology
- **Adds U.S. sterile fill-finish** capabilities, expanding our leading U.S. manufacturing footprint



Delivers a scaled, ready-made biosimilars platform—bypassing years of time, investment and risk

Attractive transaction structure balances upfront value and success-based consideration

TERMS	<ul style="list-style-type: none">• <u>Upfront considerations</u>: \$375M equity and \$375M cash• <u>Other considerations</u>: Up to \$350M in potential payments based on achievement of certain regulatory milestones, potential royalties based on commercial milestones, and funding operations through closing
FUNDING STRUCTURE	<ul style="list-style-type: none">• Cash consideration will be funded by cash on hand and debt• Equity consideration represents ~8% dilution⁽¹⁾• Expect gross leverage of ~3.9x at end of 2026, flat to 2025, and net leverage of ~3.7x at end of 2026, compared to 3.5x at end of 2025• Minimal impact to leverage ratios; Expect net leverage below 3.0x by 2028
PATH TO CLOSE	<ul style="list-style-type: none">• Transaction has been approved by the Amneal Board of Directors and Amneal's Committee of Independent Directors as Kashiv is a related party• Committee of Independent Directors engaged industry leading management, investment banking, regulatory, and legal consultants during the due diligence and negotiation process• Subject to customary closing conditions and Amneal shareholder approval• Expected to close in the second half of 2026




Amneal's strong financial profile

	Amneal Standalone			Preliminary Combined Company Financials ⁽³⁾		
	2025 Actual	Prior 2026 Guidance ⁽¹⁾	Updated 2026 Guidance ⁽²⁾	2026	2027	2030
Net Revenue % growth	\$3.02B 8%	\$3.05B – \$3.15B 1% to 4%	\$3.05B – \$3.15B 1% to 4%	\$3.05B – \$3.15B 1% to 4%	\$3.30B – \$3.50B 7% to 13%	\$4.25B – \$4.5B 8% to 10% CAGR ⁽⁶⁾
Adjusted EBITDA ⁽⁴⁾ % growth	\$688M 10%	\$720M – \$760M 5% to 10%	\$740M – \$770M 8% to 12%	\$740M – \$770M 8% to 12%	\$820M+	\$1.15B – \$1.25B 12% to 14% CAGR ⁽⁶⁾
Adjusted Diluted EPS ⁽⁴⁾ % growth	\$0.83 43%	\$0.93 – \$1.03 12% to 24%	\$0.95 – \$1.05 14% to 27%	\$0.95 – \$1.05 14% to 27%	\$1.00+	\$1.65 – \$1.85 18% to 20% CAGR ⁽⁶⁾
Operating Cash Flow	\$340M	\$325M – \$375M	\$350M – \$400M	\$300M – \$350M⁽⁵⁾	\$350M+	\$700M+


1. FY 2026 guidance as of Q4'25 Earnings Call on February 27, 2026, and assumes ~330 million weighted-average diluted shares outstanding for the year ending December 31, 2026.
2. FY 2026 guidance as of Q1'26 Earnings Call on April 22, 2026, and assumes ~330 million weighted-average diluted shares outstanding for the year ending December 31, 2026.
3. Combined Company Financials for 2026, 2027 and 2030 assumes closing of Kashiv BioSciences acquisition in second half of 2026.
4. Adjusted EBITDA and Adjusted Diluted EPS are non-GAAP measures. Refer to non-GAAP reconciliations in the appendix. Assumes weighted average diluted shares outstanding of ~345 million in 2026, ~365 million in 2027 and ~380 million in 2030 for the combined company, compared to 325 million shares outstanding in 2025.
5. Reflects estimated ~\$25M in transaction and integration costs and ~\$25M additional working capital and other costs related to the Kashiv BioSciences acquisition in 2026.
6. Reflects expected CAGR from 2027 to 2030.

Accelerates Amneal toward goal of becoming America's #1 affordable medicines company




Global biosimilars market expanding from ~\$40B to ~\$191B

GLOBAL BIOSIMILAR MARKET EXPECTED TO GROW ~5X⁽¹⁾



U.S. LOEs⁽²⁾ OF \$234B FOR 118 BIOLOGICS AND WORLDWIDE LOEs OF \$300B+ OVER NEXT 10 YEARS⁽³⁾



1. Management estimates based on research reports from Statifacts and Precedence Research on biosimilar market size from 2025 to 2035.
 2. LOE = Loss of exclusivity.
 3. IQVIA report: "Assessing the Biosimilar Void in the U.S.," Feb. 2025.

Biosimilars represent next wave of U.S. affordable medicines



INCREASED U.S. ADOPTION

Improves patient access by 2x or more⁽¹⁾
Drives **substantial savings to U.S. healthcare system** with ~\$20B estimated savings in 2024 alone⁽²⁾

80%+

adoption for most molecules⁽³⁾

IMPROVED R&D CYCLE & LOWER COST

Updated FDA Guidance to **reduce Phase 3 and streamline PK requirements**
Time to market **reduced by ~two years**

R&D cost reduced from
~\$150M to ~\$75M⁽⁴⁾

R&D time with new guidance goes from
~7 to ~5 years

LIMITED COMMERCIAL INTENSITY

Majority of opportunities have < \$10B biologic sales, **with modest biosimilar competition expected** (e.g. 3-4 each)⁽⁵⁾
Compared to 150+ for some Gx product

~10 global players

1. 2025 U.S. Generics and Biosimilars Medicines Savings Report.
2. JAMA article "Breaking the Biosimilar Bottleneck," March 9, 2026, Makary et al.
3. IQVIA sales data for existing biosimilar molecules as March 2026.
4. FDA Draft Guidance: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Oct. 2025); Clinical Leader: U.S. Biosimilars Surge: 2025.
5. IQVIA report: "Assessing the Biosimilar Void in the U.S.," Feb. 2025.

Transaction positions Amneal as a global biosimilar leader

Amneal joins a group of several fully integrated global biosimilar companies

SANDOZ

SAMSUNG BIOEPIS

CELLTRION

Amneal

AMGEN

Biocon

FRESENIUS KABI



VERTICAL INTEGRATION IS A COMPETITIVE STRENGTH



No clear market leader in U.S. biosimilars today



Portfolio selection and fast R&D execution drives speed to market



Capture complete economics vs. partnership structure

Enhances Amneal's leadership position in Affordable Medicines

BUILT LEADERSHIP IN AFFORDABLE MEDICINES

#3

Ranked U.S. Retail generics business

20-30

launches per year

280+

products across dosage forms

#1

CGT approvals since 2018⁽¹⁾

EXPANDING OUR
SUCCESSFUL PLAYBOOK IN
AFFORDABLE MEDICINES

BUILDING GLOBAL LEADER IN BIOSIMILARS

6

commercial biosimilars
expected by 2027

4

biologics manufacturing
and R&D facilities (2 in the U.S.)

20+

biosimilar pipeline programs

100+

markets worldwide
through partners



Track record launching and
sustaining complex medicines



Best-in-class in-house R&D and
manufacturing capabilities



Established supply chain and
manufacturing infrastructure



Proven commitment to improving
patient access and affordability

Complementary capabilities create a global biosimilar leader



DEVELOPMENT

In-house end-to-end

biologic development from cell line to approval (analytical, clinical & regulatory)

- 2** U.S. FDA-approved oncology biosimilars
- 3** more awaiting approval, including bXOLAIR which is already approved in U.K. by MHRA⁽¹⁾
- 20+** biosimilar candidates across therapeutic areas

MANUFACTURING

Scaled biologics platform

allowing for parallel R&D and commercial production for multiple products with 12-15 manufacturing suites

4 global facilities

across U.S. & India, with biologics capabilities for drug substance, drug product & drug/device combination

Expect about 75,000L drug substance capacity by end of 2028

COMMERCIALIZATION

Built commercial engine

leveraging strong Gx + Specialty infrastructure

Established commercial

presence with Amneal's leading portfolio of ~300 products and 20+ year customer relationships to utilize private label and market access for biosimilars

Builds on a 10+ year partnership and well-positioned to capture large biologic LOE opportunity

Combined biosimilar portfolio targets \$100B+ opportunity

	BIOSIMILAR	BIOLOGIC	THERAPEUTIC AREA	U.S. MARKET SIZE ⁽¹⁾
~\$14B TAM 6 commercial biosimilars expected by 2027	ALYMSYS ^{®(2)}	Avastin [®]	Oncology	\$1.8B
	RELEUKO [®]	NEUPOGEN	Oncology	\$0.4B
	FYLNETRA [®] PFS, OBI & AI	Neulasta [®]	Neutropenia	\$1.9B
	BONCRESA ^{™(2)}	Prolia [®]	Osteoporosis	\$3.5B
	OZILTUS ^{™(2)}	XGEVA [®]	Bone cancer	\$1.5B
	omalizumab	XOLAIR [®]	Asthma & Allergies	\$4.6B
~\$42B TAM 6+ advanced pipeline products expected approvals 2028 to 2030	abatacept	ORENCIA [®]	Immunology	\$3.9B
	certolizumab	CIMZIA [®]	Immunology	\$1.9B
	KSHB011	Undisclosed	Hematology	< \$5B
	pembrolizumab	KEYTRUDA [®]	Oncology	\$19.4B
	nivolumab	OPDIVO [®]	Oncology	\$6.0B
	dulaglutide	TRULICITY [®]	Diabetes	\$9.7B
~\$63B TAM⁽³⁾ 10+ pipeline products expected approval 2030+	dupilumab	DUPIXENT [®]	Respiratory	\$21.8B
	risankizumab	SKYRIZI [®]	Immunology	\$25.7B
	guselkumab	TREMFYA [®]	Immunology	\$9.0B
	KSHB016	Undisclosed	Rheumatology	< \$5B
	KSHB017	Undisclosed	Hematology	< \$5B
	KSHB018	Undisclosed	Rheumatology	< \$5B
	KSHB019	Undisclosed	Metabolic	< \$5B

Strategic portfolio mix of < \$5B molecules and select large-market opportunities

Note: Selected new product launches listed. Additional opportunities not disclosed. All trademarks are the property of their respective owners.

1. Reflects trailing twelve months sales per IQVIA as of January 2026 for the U.S. biosimilar market; Additive international opportunities through partners . Market size reflects the total market across all approved indications.
2. Partnered with mAbxience.
3. Reflects U.S. TAM for development programs listed, other programs not included.

Upcoming near-term opportunities from Kashiv BioSciences

	Lanreotide gSomatuline Depot	Omalizumab bXOLAIR	Abatacept bORENCIA	Certolizumab bCIMZIA	Undisclosed
THERAPEUTIC AREA	Endocrinology & Oncology	Asthma & Allergy	Immunology	Immunology	Hematology
U.S. PATIENT POPULATION	~200K	~16M	~1.3M	~1.8M	~30K
U.S. MARKET SIZE⁽¹⁾	\$0.9B	\$4.6B	\$3.9B	\$1.9B	< \$5B
WW MARKET SIZE⁽¹⁾	\$1.7B	\$5.9B	\$5.0B	\$2.8B	< \$5B
PRODUCT TYPE	PFS	Vial, PFS, AI	Vial, PFS, AI	Vial, PFS, AI	Vial
IMPORTANCE AND KEY ADVANTAGES	Growing GEP-NET ⁽²⁾ and acromegaly market with on-going market shortage	Access to a proven therapy with both indications in fast growing market ⁽³⁾	Supports broader access to long-term autoimmune treatment options	Improves affordability and continuity of care for inflammatory diseases	Established standard of care with durable demand
EXPECTED APPROVAL	2026	2027	2028 – 2029		



1. Reflects trailing twelve months sales per IQVIA as of January 2026 for the U.S. and worldwide biosimilar market as of IQVIA MAT Q2 2025. Market size reflects the total market across all approved indications.
2. GEP-NET = GastroEnteroPancreatic NeuroEndocrine Tumors.
3. Already approved by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). Pending EMA and FDA approval

Combination is highly synergistic in several strategic areas

COMMERCIAL & OPERATIONAL SYNERGIES

- **Leverages commercial capabilities in Specialty (market access) and Retail (private label)**, where we expect most future contracting to occur
- **Increases presence in U.S. hospital market** by expanding portfolio of injectables & 505(b)(2) products with much-needed biologics
- **Expands international business meaningfully** with Kashiv's global product development and out-licensing, synergistic to Amneal's model
- **Combined global infrastructure** increases speed to market at lower cost and expands R&D capabilities



FINANCIAL SYNERGIES

- **Eliminates the need to invest hundreds of millions of dollars over years to build a biosimilars platform**
- **Unlocks \$150M+ in expected tax and local benefits** over time
- **\$300M+ estimated savings from eliminating milestones & profit sharing by 2030** related to existing licensing (bXOLAIR, lanreotide, etc.)
- **Additional operating expense savings and efficiencies**

**\$400M-
\$500M**

expected total financial
benefits over time

Beyond traditional cost synergies, this transaction creates strategic scale and long-term value

Extending Amneal's superb track record of diversification and financial strength


		2019	2025	2030 ⁽²⁾
Substantial & durable growth	Net Revenue	\$1.6B	\$3.02B	\$4.25B - \$4.5B
	Adjusted EBITDA ⁽¹⁾	\$339M	\$688M	\$1.15B - \$1.25B
	Operating Cash Flow	\$2M	\$340M	\$700M+
	Net leverage	7.4x	3.5x	< 3x
Diversified & expanding portfolio	Affordable Medicines products	225+	280+	400+
	Pending ANDAs (% complex)	97 (44%)	59 (64%)	~50 (~80%)
	Biosimilars products	3 pipeline	3 commercial, 2 approved, 1 pending	12+ commercial, 20+ pipeline
	Specialty products ⁽³⁾	2 (RYTARY® & UNITHROID®)	4 (plus CREXONT® & Brekiya®)	6 (4 existing plus 2 undisclosed)

1. Adjusted EBITDA is a non-GAAP measure. Refer to non-GAAP reconciliations in the appendix.

2. Growth projection reflects the potential outcomes of delivering our long-term strategy and is based on the current macro environment and expected product pipeline launches, among other assumptions. Assumes Kashiv BioSciences deal close.

3. Reflects promoted brands in the Specialty business.

In summary, acquisition creates a global biosimilar leader



HIGHLY STRATEGIC & COMPLEMENTARY TRANSACTION

Direct access to **\$300B+ global biologic LOEs over next decade** – with \$234B in U.S.

Well positioned as integrated biosimilar leader with **seamless integration** of Kashiv's R&D & manufacturing with Amneal's commercial scale

Low execution risk as it builds on ten-year plus relationship



COMBINED BIOSIMILAR PORTFOLIO AND CAPABILITIES

Multiple biosimilar launches each year – growing over time

20+ biosimilar pipeline projects – mix of large biologics and smaller < \$5B molecules

Robust R&D capabilities enables parallel development and commercialization



DIVERSIFIES AND EXTENDS AMNEAL'S GROWTH PROFILE

Adds biosimilars as a key **growth pillar** within Affordable Medicines

Accelerates **international expansion and growth**

Extends Amneal's durable growth profile into 2030s



ATTRACTIVE DEAL STRUCTURE AND SIGNIFICANT SYNERGIES

Prudent mix of upfront consideration (cash & equity) and **potential success-based milestones** over time

Minimal impact to leverage profile with **clear path to be below 3x net leverage by 2028**

Substantial financial synergies

Preliminary Q1 2026 Results

Preliminary Q1 2026 results

\$ millions (except per share data)	Q1 2026	Q1 2025	Change
Net Revenue	\$723	\$695	+4%
Adjusted Gross Margin ⁽¹⁾	48.2%	43.1%	+510 bps
Adjusted EBITDA ⁽¹⁾	\$202	\$170	+19%
Adjusted EPS ⁽¹⁾	\$0.27	\$0.21	+29%

Note: The Q1'26 preliminary financial results are based on the most recent information available to the Company's management. Such preliminary financial results are forward-looking statements. Actual results may differ from these preliminary financial results due to the completion of the Company's financial close procedures, final accounting adjustments and other developments that may arise between the date of the Form 8-K and the time that financial results for Q1'26 are finalized, and such differences may be material. The preliminary financial results for Q1'26 are not necessarily indicative of the results to be achieved in any future period.

(1) Please see the language under the heading "Non-GAAP Financial Measures" in today's presentation for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures.

Q1 2026 total net revenue and performance by segment

\$ millions	Q1 2026	Q1 2025	Change	Notes
Total Company	\$723	\$695	+4%	<ul style="list-style-type: none"> Driven by strong performance of high-margin products across the portfolio
Affordable Medicines	\$423	\$415	+2%	<ul style="list-style-type: none"> Strong revenues of key products, including for Women's Health & ADHD
Specialty	\$133	\$108	+23%	<ul style="list-style-type: none"> Driven by strong revenues for CREXONT® \$21M and Brekiya® \$5M
AvKARE	\$166	\$172	(4%)	<ul style="list-style-type: none"> Government growth offset by distribution, as expected

Note: The Q1'26 preliminary financial results are based on the most recent information available to the Company's management. Such preliminary financial results are forward-looking statements. Actual results may differ from these preliminary financial results due to the completion of the Company's financial close procedures, final accounting adjustments and other developments that may arise between the date of the Form 8-K and the time that financial results for Q1'26 are finalized, and such differences may be material. The preliminary financial results for Q1'26 are not necessarily indicative of the results to be achieved in any future period.

Continued deleveraging

\$ millions	Mar 31, 2026	Dec 31, 2025	Mar 31, 2025
Gross debt ⁽¹⁾	\$2,690	\$2,695	\$2,568
Total cash ⁽²⁾	\$198	\$282	\$59
Net debt ⁽³⁾	\$2,492	\$2,413	\$2,509
Adjusted EBITDA ⁽⁴⁾	\$720	\$688	\$645
Gross leverage ⁽⁵⁾	3.7x	3.9x	4.0x
Net leverage ⁽⁶⁾	3.5x	3.5x	3.9x

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

(1) Includes Term Loan B (TLB) maturities due in 2032, and borrowings under the revolving credit facilities due in 2030.

(2) Includes cash and cash equivalents, and excludes restricted cash.

(3) Net debt = Gross debt less total cash.


(4) Please see the language under the heading "Non-GAAP Financial Measures" in today's presentation for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures.

(5) Calculated by dividing gross debt by adjusted EBITDA for the year ended March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

(6) Calculated by dividing net debt by adjusted EBITDA for the year ended March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

Amneal

Combination of Amneal & Kashiv creates a global infrastructure



Significant phase of new launches in Affordable Medicines

	New Product	Dosage Form	Therapeutic Area	Brand	IQVIA ¹	Approval	Launch
	Lenalidomide	Capsule	Hematology / Oncology	Revlimid®	\$6.3B ⁽²⁾	Q1'25	Q1'26
	Rifaximin	Tablet	Gastroenterology	Xifaxan®	\$2.9B ⁽²⁾	Q1'25	Undisclosed
	Mesalamine DR	Tablet	Gastroenterology	Asacol® HD	\$81M	Q1'25	Q1'25
	Everolimus	Tablet	Oncology	Afinitor®	\$167M	Q1'25	Q1'25
	Prednisolone acetate	Ophthalmic	Ophthalmology	Pred-Forte®	\$200M	Q2'25	Q4'25
	Sodium oxybate	Oral solution	Neurology (narcolepsy)	Xyrem®	n/a ⁽³⁾	Q3'25	Q1'26
	Bimatoprost	Ophthalmic	Ophthalmology	Lumigan®	\$676M	Q3'25	Q2'26
	Risperidone ER	Vial	Psychiatry	Risperdal Consta®	\$178M	Q3'25	Q1'26
	Beclomethasone dipropionate	Inhalation	Respiratory (asthma)	QVAR®	\$321M	Q4'25	Q1'26
	Iohexol (2 sizes)	Vial	Diagnostic	Omnipaque®	\$658M ⁽²⁾	Q4'25	Q2'26
	Cyclosporine	Ophthalmic	Ophthalmology	Restasis®	\$2.3B	Q4'25	Q1'26
	Albuterol sulfate	Inhalation	Respiratory (asthma)	ProAir® HFA	\$1.5B	Q4'25	Q2'26
	Denosumab biosimilars	Vial	Osteoporosis/Bone Cancer	PROLIA® & XGEVA®	\$5.4B	Q4'25	Undisclosed
	Epinephrine (2 presentations)	MDV/SDV	Emergency/Critical Care	Adrenalin®	\$109M	Q4'25	Q1'26
Approved	Eltrombopag	Tablet	Hematology	Promacta®	\$1.3B	Q1'26	Q1'26
Estimated	Sodium Bicarbonate	IV Bag	Critical Care	Neut®	\$119M	Q2'26 ⁽⁴⁾	Q2'26 ⁽⁵⁾
	Lanreotide injection	PFS	Endocrinology/Oncology	Somatuline® Depot	\$927M	Q3'26 ⁽⁴⁾	Q3'26 ⁽⁵⁾
	Romidepsin injection	Vial	Oncology	Romidepsin	\$76M	Q3'26 ⁽⁴⁾	Undisclosed
	Iohexol (additional sizes)	Vial	Diagnostic	Omnipaque®	\$658M ⁽²⁾	Q3'26 ⁽⁴⁾	Q3'26 ⁽⁵⁾
	Epinephrine (3rd presentation)	PFS	Emergency/Critical Care	Adrenalin®	\$109M	Q4'26 ⁽⁴⁾	Q4'26 ⁽⁵⁾
	Omalizumab biosimilar	PFS	Immunology/Allergy	XOLAIR®	\$4.6B	Q4'26 ⁽⁴⁾	Undisclosed

Note: Selected new product launches listed. Additional opportunities not disclosed. All trademarks are the property of their respective owners.

PFS = Prefilled Syringe; MDV = Multiple-dose vial; RTU = Ready-to-use; SDV = Single-dose vial; BLA = Biologics License Application.

(1) Reflects trailing twelve months sales per IQVIA as of the most recent period. (2) Market size reflects the total market across all approved indications. Our product is approved for a subset of these indications. (3) Distributed through Specialty Pharmacy, not captured in IQVIA. (4) Not yet approved, estimated approval date. (5) Not yet launched, estimated launch date.

Reconciliation of net income (loss) to EBITDA and adjusted EBITDA

(\$ in millions, unaudited)	Three Months Ended March 31,		Year Ended December 31,	
	2026 (Preliminary)	2025	2025	2019 ⁽¹⁾
Net income (loss)	\$ 78.0	\$ 24.6	\$ 127.9	\$ (603.6)
Adjusted to add:				
Interest expense, net	53.4	56.9	241.1	168.2
Provision for income taxes	2.2	12.9	11.3	383.3
Depreciation and amortization	43.2	60.2	223.6	207.2
EBITDA (Non-GAAP)	\$ 176.7	\$ 154.6	\$ 603.9	\$ 155.2
Adjusted to add (deduct):				
Stock-based compensation expense	8.8	7.1	31.8	21.7
Acquisition, site closure, and idle facility expenses	5.7	1.2	5.3	73.5
Restructuring and other charges	0.5	0.6	4.2	34.3
Loss on refinancing	3.5	—	31.4	—
Inventory related charges	—	—	—	25.7
Charges (credit) related to legal matters, net	0.7	—	(0.4)	12.6
Asset impairment charges	—	0.1	23.0	175.2
Foreign exchange loss (gain)	7.8	(4.2)	(7.6)	5.0
Amortization of upfront payment	—	—	—	36.4
Gain on sale of business	—	—	—	(7.3)
(Decrease) increase in tax receivable agreement liability	(2.3)	10.7	6.6	(192.9)
Other	0.6	(0.1)	(9.7)	(0.4)
Adjusted EBITDA (Non-GAAP)	\$ 202.0	\$ 170.0	\$ 688.4	\$ 339.0



Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

(1) Beginning in the first quarter of 2022, we no longer excluded research and development milestone expenses related to license and collaboration agreements from our non-GAAP financial measures and our line item components. Adjusted results for the year ended December 31, 2019 have been revised to reflect this change.

Reconciliation of net income to EBITDA and adjusted EBITDA

(\$ in millions, unaudited)	Three Months Ended				Last Twelve Months Ended
	June 30, 2025	September 30, 2025	December 31, 2025	March 31, 2026 (Preliminary)	March 31, 2026 (Preliminary)
Net income	\$ 35.6	\$ 18.1	\$ 49.6	\$ 78.0	\$ 181.3
Adjusted to add:					
Interest expense, net	65.1	62.8	56.2	53.4	237.5
Provision for (benefit from) income taxes	16.1	(23.4)	5.7	2.2	0.6
Depreciation and amortization	60.1	54.1	49.2	43.2	206.6
EBITDA (Non-GAAP)	\$ 176.9	\$ 111.7	\$ 160.7	\$ 176.7	\$ 626.0
Adjusted to add (deduct):					
Stock-based compensation expense	8.3	8.2	8.2	8.8	33.5
Acquisition, site closure, and idle facility expenses	1.2	2.3	0.5	5.7	9.7
Restructuring and other charges	1.0	0.1	2.5	0.5	4.1
Loss on refinancing	—	31.4	—	3.5	34.9
(Credit) charges related to legal matters, net	(0.4)	—	—	0.7	0.3
Asset impairment charges	—	22.8	0.1	—	22.9
Foreign exchange (gain) loss	(8.3)	3.4	1.4	7.8	4.4
Increase (decrease) in tax receivable agreement liability	4.4	(20.8)	12.3	(2.3)	(6.4)
Other	0.4	0.5	(10.6)	0.6	(9.1)
Adjusted EBITDA (Non-GAAP)	\$ 183.7	\$ 159.6	\$ 175.2	\$ 202.0	\$ 720.4



Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Calculation of last twelve months gross and net leverage

(\$ in millions, unaudited)	Last Twelve Months	Year Ended December	Last Twelve Months	Year Ended December
	March 31, 2026 ⁽¹⁾	2025 ⁽²⁾	March 31, 2025 ⁽³⁾	2019 ⁽⁴⁾
EBITDA	\$ 626	\$ 604	\$ 549	\$ 155
Adjusted EBITDA	\$ 720	\$ 688	\$ 645	\$ 339

(\$ in millions, unaudited)	March 31, 2026	December 31, 2025	March 31, 2025	December 31, 2019
Term loan due 2032 ⁽⁵⁾	\$ 2,090	\$ 2,095	\$ —	\$ —
Senior notes due 2032 ⁽⁵⁾	600	600	—	—
Term loan due May 2025 ⁽⁵⁾	—	—	—	2,659
Term loan due May 2028 ⁽⁵⁾	—	—	2,278	—
2023 Revolving credit facility ⁽⁵⁾	—	—	290	—
Gross debt	\$ 2,690	\$ 2,695	\$ 2,568	\$ 2,659
Less: Cash and cash equivalents	(198)	(282)	(59)	(151)
Net debt	\$ 2,492	\$ 2,413	\$ 2,509	\$ 2,508

	Last Twelve Months	Year Ended December	Last Twelve Months	Year Ended December
	March 31, 2026	2025	March 31, 2025	2019
Gross leverage ⁽⁶⁾	3.7x	3.9x	4.0x	7.8x
Net leverage ⁽⁷⁾	3.5x	3.5x	3.9x	7.4x

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

(1) Refer to the Company's 8-K filed with the SEC on April 22, 2026 for a complete reconciliation of our GAAP to non-GAAP preliminary results.

(2) Refer to the Company's 8-K filed with the SEC on February 27, 2026 for a complete reconciliation of our GAAP to non-GAAP results.

(3) Refer to "Reconciliation of net income to EBITDA and Adjusted EBITDA" in this appendix for calculation of EBITDA and Adjusted EBITDA for last twelve months ended March 31, 2025.

(4) Beginning in the first quarter of 2022, the Company no longer excluded research and development milestone expenses related to license and collaboration agreements from its non-GAAP financial measures. The reconciliation of our GAAP to non-GAAP results in the Company's 8-K filed with the SEC on February 26, 2020 was adjusted accordingly for comparative purposes. Refer to "Reconciliation of net (loss) income to EBITDA and Adjusted EBITDA" herein for the comparative GAAP to non-GAAP results.

(5) Represents contractual principal due.

(6) Calculated by dividing gross debt by adjusted EBITDA for the year or the trailing twelve-month period then ended.

(7) Calculated by dividing net debt by adjusted EBITDA for the year or the trailing twelve-month period then ended.

Reconciliation of net income to EBITDA and adjusted EBITDA Last Twelve Months ending March 31, 2025

(\$ in millions, unaudited)	Three Months Ended				Last Twelve Months Ended
	June 30, 2024	September 30, 2024	December 31, 2024	March 31, 2025	March 31, 2025
Net income (loss)	\$ 16.8	\$ 11.8	\$ (20.7)	\$ 24.6	\$ 32.4
Adjusted to add:					
Interest expense, net	65.7	65.5	61.7	56.9	249.8
Provision for income taxes	3.6	3.7	5.4	12.9	25.6
Depreciation and amortization	55.6	59.0	66.1	60.2	240.8
EBITDA (Non-GAAP)	\$ 141.7	\$ 139.9	\$ 112.5	\$ 154.6	\$ 548.6
Stock-based compensation expense	6.7	7.1	7.2	7.1	28.2
Acquisition, site closure, and idle facility expenses	0.6	0.6	0.5	1.2	2.9
Restructuring and other charges	0.1	0.2	0.5	0.6	1.4
Charges (credit) related to legal matters, net	0.7	(0.1)	1.8	—	2.3
Asset impairment charges	—	0.2	0.2	0.1	0.4
Foreign exchange loss (gain)	0.3	(2.3)	7.7	(4.2)	1.4
Increase in tax receivable agreement liability	13.4	11.3	24.0	10.7	59.4
Other	(1.3)	0.8	1.0	(0.1)	0.4
Adjusted EBITDA (Non-GAAP)	\$ 162.2	\$ 157.6	\$ 155.3	\$ 170.0	\$ 645.1



Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reconciliation of net income to adjusted results

in millions except per share amounts, unaudited	Three Months Ended March 31,		Year Ended
	2026 (Preliminary)	2025	December 31, 2025
Net income	\$ 78.0	\$ 24.6	\$ 127.9
Adjusted to add (deduct):			
Non-cash interest	6.7	0.3	23.5
GAAP provision for income taxes	2.2	12.9	11.3
Amortization	29.0	44.3	162.4
Stock-based compensation expense	8.8	7.1	31.8
Acquisition, site closure, and idle facility expenses	5.7	1.2	5.2
Restructuring and other charges	0.5	0.6	4.2
Loss on refinancing	3.5	—	31.4
Charges (credit) related to legal matters, including interest, net	1.5	—	(0.4)
Asset impairment charges	—	0.1	23.0
(Decrease) increase in tax receivable agreement liability	(2.3)	10.7	6.6
Other	0.6	—	(9.7)
Provision for income taxes	(28.8)	(22.8)	(92.5)
Net income attributable to non-controlling interests not associated with our class B common stock	(15.7)	(12.4)	(55.9)
Adjusted net income (Non-GAAP)	\$ 89.7	\$ 66.5	\$ 268.9
Weighted average diluted shares outstanding (Non-GAAP)	328.9	324.0	324.8
Diluted EPS (GAAP)	\$ 0.19	\$ 0.04	\$ 0.22
Adjusted diluted earnings per share (Non-GAAP)	\$ 0.27	\$ 0.21	\$ 0.83



Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reconciliations of COGS and gross profit to adjusted results

(\$) in millions, unaudited	Three Months Ended March 31, 2026 (Preliminary)			Three Months Ended March 31, 2025		
	GAAP	Adjustments	Non-GAAP	GAAP	Adjustments	Non-GAAP
Net revenue	\$ 722.5	\$ —	\$ 722.5	\$ 695.4	\$ —	\$ 695.4
Cost of goods sold ⁽¹⁾	402.4	(28.3)	374.1	439.5	(43.5)	396.0
Gross profit	320.1	28.3	348.4	255.9	43.5	299.4
Gross margin %	44.3 %		48.2 %	36.8 %		43.1 %



Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

(1) Adjustments for the three months ended March 31, 2026 (preliminary) and 2025, respectively, were comprised of stock-based compensation expense (\$1.0 million and \$0.9 million), amortization expense (\$27.3 million and \$42.5 million), and asset impairment charges (none and \$0.1 million).